Overview
In this talk, Dr. Dasgupta explains the pleiotropic role of Interleukin-6 (IL-6) in Giant cell arteritis (GCA) pathogenesis, clinical benefits & therapeutic efficacy of Tocilizumab (IL-6 inhibitor) for treating GCA. Published data demonstrated that tocilizumab enables sustained remission with rapid glucocorticoid tapering over 6 months in GCA patients.
Faculty
Dr. Bhaskar Dasgupta
M.D. F.R.C.P
Consultant Rheumatologist & Clinical Director R&D; Southend University Hospital NHS Foundation Trust MSK Research Specialty co-lead, North Thames Clinical Research Network; Honorary Professor University of Essex, Honorary Professor Queen Mary University London.Resources
External Resources
Role of IL-6 Inhibition in Giant Cell Arteritis
Also Read
.webp?updated=20250515071407)
